Related references
Note: Only part of the references are listed.Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism
Mahlon D. Johnson et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit
Tzu-Yin Lin et al.
BLOOD (2010)
HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity
Vivek Sharma et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Epidemiology and etiology of meningioma
Joseph Wiemels et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Effect of tumor removal on tinnitus in patients with vestibular schwannoma Clinical article
Katsuharu Kameda et al.
JOURNAL OF NEUROSURGERY (2010)
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma
Sylwia Ammoun et al.
NEURO-ONCOLOGY (2010)
Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
Scott R. Plotkin et al.
OTOLOGY & NEUROTOLOGY (2010)
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
David M. Lucas et al.
PLOS ONE (2010)
Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2
D. Gareth Evans et al.
CLINICAL CANCER RESEARCH (2009)
Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells
Tina X. Lee et al.
EUROPEAN JOURNAL OF CANCER (2009)
Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ
David A. Hilton et al.
HISTOPATHOLOGY (2009)
Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas
Mahlon D. Johnson et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Scott R. Plotkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Neurofibromatosis type 2 (NF2): A clinical and molecular review
D. Gareth R. Evans
ORPHANET JOURNAL OF RARE DISEASES (2009)
Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex
Andrea I. McClatchey et al.
TRENDS IN CELL BIOLOGY (2009)
A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
Ya-Ting Yang et al.
NEOPLASIA (2009)
OSU-HDAC42, a Histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model
Aaron M. Sargeant et al.
CANCER RESEARCH (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma
Abraham Jacob et al.
OTOLOGY & NEUROTOLOGY (2008)
Nf2/Merlin: a coordinator of receptor signalling and intercellular contact
M. Curto et al.
BRITISH JOURNAL OF CANCER (2008)
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
Yen-Shen Lu et al.
HEPATOLOGY (2007)
Histone deacetylase inhibitors induce cell death selectively in cells that Harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21
Lidija Klampfer et al.
CANCER RESEARCH (2007)
Ribotoxic stress sensitizes glioblastoma cells to death receptor-induced apoptosis:: Requirements for c-Jun NH2-terminal kinase and Bim
Shuli Xia et al.
MOLECULAR CANCER RESEARCH (2007)
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Marcello Curto et al.
JOURNAL OF CELL BIOLOGY (2007)
Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application
V. Santini et al.
CURRENT DRUG METABOLISM (2007)
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood
Sarah E. Furchert et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
Weisheng Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer
Samuel K. Kulp et al.
CLINICAL CANCER RESEARCH (2006)
Valproic acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts
Qin Shu et al.
CLINICAL CANCER RESEARCH (2006)
The tumor suppressors merlin and expanded function cooperatively to modulate receptor endocytosis and signaling
S Maitra et al.
CURRENT BIOLOGY (2006)
Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells
HO Jin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
被撤回的出版物: The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide (Retracted article. See vol. 95, pg. 336, 2019)
RR Rosato et al.
MOLECULAR PHARMACOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Histone deacetylase inhibitors: discovery and development as anticancer agents
PA Marks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC
XN Li et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Mitogenic signal transduction pathways in meningiomas: Novel targets for meningioma chemotherapy?
M Johnson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes
CS Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Establishment of a benign meningioma cell line by hTERT-mediated immortalization
S Püttmann et al.
LABORATORY INVESTIGATION (2005)
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-jun n-terminal kinase 1 activation
Y Dai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Sudden sensorineural hearing loss as a revealing symptom of vestibular schwannoma
E Sauvaget et al.
ACTA OTO-LARYNGOLOGICA (2005)
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas
C Mawrin et al.
CLINICAL CANCER RESEARCH (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
JS Ungerstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A NHERF binding site links the βPDGFR to the cytoskeleton and regulates cell spreading and migration
MF James et al.
JOURNAL OF CELL SCIENCE (2004)
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
A Villar-Garea et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions
PP Roux et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2004)
Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
RW Johnstone et al.
CANCER CELL (2003)
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells
K Kaempchen et al.
HUMAN MOLECULAR GENETICS (2003)
Acoustic neuroma in patients with completely resolved sudden hearing loss
BI Nageris et al.
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2003)
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxarmic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
R Nimmanapalli et al.
BLOOD (2003)
Surgical treatment of nocardial brain abscesses
GYF Lee et al.
NEUROSURGERY (2002)
Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts
LS Chang et al.
GENOMICS (2002)
Vestibular schwannoma with malignant transformation: A case report
EI Son et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2001)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
Inhibitors of histone deacetylase as new anticancer agents
M Jung
CURRENT MEDICINAL CHEMISTRY (2001)
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling
RJ Shaw et al.
DEVELOPMENTAL CELL (2001)
Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin
PA Wade
HUMAN MOLECULAR GENETICS (2001)
Share Paper
